BEIJING & LES ULIS, France--(BUSINESS WIRE)--Yabao Pharmaceutical Co, Inc. (Shanghai Stock Exchange: 600351), a leading pharmaceutical company in China, and LFB Biomedicaments, a fully-owned subsidiary of LFB SA, a French state-owned company, today announced a strategic partnership to deliver LFB’s leading human albumin product VIALEBEX® to China, which is the world’s largest human albumin market with annual growth of 29% from 2010 to 2014.
Under the terms of the agreement, Yabao receives exclusive rights to register VIALEBEX® at the China Food and Drug Administration (CFDA) and further commercialize VIALEBEX® in China. LFB shall exclusively supply VIALEBEX® to Yabao using their specific expertise in bioproduction and biosafety. Financial terms were not disclosed.
"LFB’s VIALEBEX® is a human albumin already registered and marketed in Europe and worldwide. Yabao is honored to be collaborating with a long-established, global leader in human albumin and plasma-derived medicinal products," commented Dr. Peng Wang, President of R&D and Head of International Business, Yabao Pharmaceutical Co., "This ground-breaking commercial partnership with LFB is an important sign of Yabao's growing commitment to bringing world-class products such as VIALEBEX® to China. Yabao is pleased to serve the growing need for high-quality human albumin to treat patients suffering from serious diseases in China."
Dr Philippe Gredy, MD, MSc, Executive VP Marketing and Sales, stated, "We consider Yabao as a very valuable partner and are very pleased to have been chosen for our biopharmaceutical expertise. China is part of our strategy to grow internationally and we will do our best to serve the Chinese patients with high-quality medicinal products."
About Yabao Pharmaceutical Co.
Yabao Pharmaceutical Co. (Shanghai Stock Exchange 600351) is a leading Chinese pharmaceutical company with fully-integrated development, manufacturing, and commercialization capabilities. Yabao recently has been pursuing strategic development and commercialization partnerships to bring high-quality innovative or generic medicines into China. In addition to strong clinical and regulatory capabilities, Yabao has extensive expertise in formulation and API production and meets current Good Manufacturing Practice (cGMP) requirements with two manufacturing sites approved by U.S. FDA and a European agency, respectively. For more information about Yabao Pharmaceutical Co., please visit www.yabao.com.cn
LFB is a biopharmaceutical group that develops, manufactures, and markets medicinal products indicated in the treatment of serious and often rare diseases in hemostasis, immunology, and intensive care. Number one in France and in 6th place worldwide in the field of plasma-derived medicinal products, the LFB group is also one of the leading European companies in the development and production of proteins and of innovative treatments based on biotechnology. With a sustained research effort, the LFB group has a growth strategy that seeks to extend its activities at an international level. The LFB group currently markets products in 40 countries around the world and had a global turnover of 502 million euros in 2014. www.groupe-lfb.com
VIALEBEX® is used for restoration and maintenance of circulating blood volume in cases of demonstrated hypovolemia when use of a colloid is appropriate.
The choice to use albumin rather than an artificial colloid should be made based on the patient’s clinical condition and official recommendations.
VIALEBEX® is manufactured through a rigorously-controlled process conforming to specifications of European Pharmacopeia. Fractionation way and specific purification steps processed in VIALEBEX® are designed to provide an albumin with preserved properties of native human albumin, associated with a biosafety which is recognized for more than 20 years.